August 08, 2025

Genetic Risk of Takayasu Arteritis Mapped

Large-scale genetic analyses identify multiple susceptibility loci for Takayasu arteritis, confirming HLA-B*52 as the strongest association and revealing immune pathways that vary by ancestry.

Conexiant

August 08, 2025

Unprompted Speech Changes Found in ME/CFS

Nearly 1 in 10 individuals with myalgic encephalomyelitis/chronic fatigue syndrome reported voice or speech changes in a recent survey, despite not being directly asked about these symptoms.

Conexiant

August 07, 2025

PsA Patients Accurately Report Nonjoint Symptoms

Patients with psoriatic arthritis consistently identify nonjoint symptoms such as dactylitis, psoriasis, and uveitis, demonstrating the clinical utility of patient-reported outcome measures.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

July 30, 2025

JAK Inhibitors May Improve Artery Health Markers

JAK inhibitor therapy targets inflammation and correlates with improvements in carotid artery measurements, while baseline vascular markers continue to predict cardiovascular risk.

Conexiant

August 04, 2025

Mood Shift Linked to Shoulder Pain Relief

Patients undergoing shoulder arthroplasty for rheumatoid arthritis show significant pain and function improvement, and data suggest emotional status may influence recovery dynamics over time.

Conexiant

July 28, 2025

Biportal and Uniportal Endoscopy Compared in Trial 

The trial investigates how biportal and uniportal endoscopic approaches differ in postoperative disability, imaging results, and recovery metrics for lumbar spinal stenosis.

Conexiant

July 31, 2025

Guselkumab Improves Scalp Psoriasis in Patients With Skin of Color

This clinical trial summary highlights the efficacy, safety, and sustained scalp clearance achieved with guselkumab for moderate to severe scalp psoriasis in patients with skin of color.

Conexiant

July 31, 2025

FDA Approves Implantable Device for RA

“The approval of the SetPoint System, the first-in-class neuroimmune modulation platform, represents a transformative milestone in the management of autoimmune diseases."

Conexiant